SII will acquire a 20% stake in IntegriMedical to advance the technology. Credit: T. Schneider / Shutterstock.com.

Vaccine manufacturer the Serum Institute of India (SII) has announced plans to make a strategic investment in IntegriMedical, acquiring a stake of 20%, to progress the development of needle-free injection system (N-FIS) technology.

The investment aligns with SII’s strategy to enhance patient compliance, lower needle-stick injuries and improve the efficacy of liquid medications.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

N-FIS technology employs a mechanically powered high-velocity jet stream to administer drugs and biologics.

The system is designed to offer a pain-free experience to patients, particularly those with needle phobia, making the process of medication administration more pleasant and stress-free.

N-FIS has secured regulatory approvals in India, Europe and the US. It holds International Organisation for Standardisation 13485 certification and a US patent.

See Also:

Clinical trials have demonstrated the technology’s ability to reduce pain and address needle-phobia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The collaboration will combine SII’s vaccine production and global supply expertise with IntegriMedical’s research capabilities and drug delivery technology.

The N-FIS is set to be introduced to the Indian private market, providing an innovative alternative to conventional needle-based injections.

The technology’s benefits include the elimination of needle phobia, pain reduction during drug administration, ease of use and the prevention of cross-contamination.

Serum Institute of India CEO Adar Poonawalla said: “At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide.

“IntegriMedical’s needle-free injection systems (N-FIS) represent a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionise the way we administer vaccines, making the process more comfortable for patients and healthcare professionals.”